Not investment advice. Educational platform. See Disclaimer.
NYSE: DHR
Danaher Corporation
Healthcare | Medical - Diagnostics & Research
$178.94+1.69 (+0.95%)as of 2026-07-15 07:47 UTC
Market Cap$126.5B
EPS (TTM)$5.05
Danaher Corporation (NYSE: DHR) is a $126.5B medical - diagnostics & research company trading at $178.94 (+1.0% today) — 35.4× trailing earnings, yielding 0.69%. Figures from SEC EDGAR and market feeds; updated 2026-07-15 07:47 UTC.
52-Week Range
Low $175.02High $242.80
What Danaher Corporation does
Danaher is a science and technology company organized into three segments—Biotechnology, Life Sciences, and Diagnostics—comprising more than operating companies with facilities in approximately countries. The Biotechnology segment provides equipment, consumables, software and services for researching, developing, and manufacturing biological medicines, including therapies for monoclonal antibodies, proteins, vaccines, and cell and gene therapies.
Summarized from Danaher Corporation’s SEC filings · Read the filing ↗
Danaher is a science and technology company organized into three segments—Biotechnology, Life Sciences, and Diagnostics—comprising more than operating companies with facilities in approximately countries.
What is DHR's valuation?
DHR trades at $178.94, 35.43× trailing earnings, 26.60× EV/EBITDA, as of 2026-07-15. It carries a 0.69% dividend yield.
When did DHR last file with the SEC?
Danaher Corporation's most recent SEC filing on record is a 8-K filed 2026-06-03. All filings link to their SEC EDGAR originals above.
Where does this data come from?
SEC EDGAR filings and public market data feeds, fetched 2026-07-15 07:47 UTC. This page is also available as JSON at /api/data?ticker=DHR and is emitted with FAQPage structured data for machine reading.
For you
Charts, 10-year financials, peer comparison, screening and portfolio tracking for DHR and 3,500+ tickers.
